EDIT Jan 2025 17.500 put
| Previous close | 8.96 |
| Open | 8.96 |
| Bid | 10.30 |
| Ask | 10.80 |
| Strike | 17.50 |
| Expiry date | 2025-01-17 |
| Day's range | 8.96 - 8.96 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GuruFocus.comEVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024. Following this transaction, the insider has a total of 116,829 shares remaining in the company. Editas Medicine Inc is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases.
GuruFocus.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing. Editas Medicine Inc (NASDAQ:EDIT) is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases. Over the past year, the insider transaction history at Editas Medicine Inc shows a trend with 1 insider buy and 11 insider sells.
GlobeNewswireEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
